according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Cephapirin / Prednisolone Formulation

Other means of identification : Mastiplan (A011329)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Veterinary product

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or

breathing difficulties if inhaled.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

Precautionary statements : Response:

P304 + P340 IF INHALED: Remove person to fresh air and

keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a

POISON CENTER/ doctor.

Hazardous components which must be listed on the label:

Cefapirin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cefapirin	21593-23-7 244-466-5	Resp. Sens. 1A; H334	>= 1 - < 10
prednisolone	50-24-8 200-021-7	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Bone marrow, Adrenal gland, Liv- er) Aquatic Chronic 2; H411	>= 0,25 - < 1

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.1 28.09.2024 766831-00019 Date of first issue: 16.06.2016

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides Metal oxides Silicon oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

harriers)

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Keep tightly closed.
 Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Gases

7.3 Specific end use(s)

Specific use(s) : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cefapirin	21593-23-7	TWA	0.4 mg/m3 (OEB 2)	Internal
	Further information: RSEN			
prednisolone	50-24-8	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.1 28.09.2024 766831-00019 Date of first issue: 16.06.2016

Physical state : liquid, oily

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cefapirin:

Acute oral toxicity : LD50 (Mouse): 26.000 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Mouse): > 7.600 mg/kg Application Route: Intraperitoneal

1,

LD50 (Rat): 7.800 mg/kg

Application Route: Intraperitoneal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.1 28.09.2024 766831-00019 Date of first issue: 16.06.2016

prednisolone:

Acute oral toxicity : LD50 (Mouse): 1.680 mg/kg

LD50 (Rat): > 3.857 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): 147 mg/kg

Application Route: Subcutaneous

LD50 (Mouse): 767 mg/kg

Application Route: Intraperitoneal

Skin corrosion/irritation

Not classified based on available information.

Components:

prednisolone:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

prednisolone:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefapirin:

Assessment : Probability or evidence of high respiratory sensitisation rate in

humans

prednisolone:

Remarks : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefapirin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

prednisolone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Test Type: sister chromatid exchange assay

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat

Application Route: Oral

Result: negative

Test Type: sister chromatid exchange assay

Species: Humans Result: negative

Carcinogenicity

Not classified based on available information.

Components:

prednisolone:

Species : Rat
Application Route : Oral
Exposure time : 18 Months
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Cefapirin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intraperitoneal injection Fertility: LOAEL: > 500 mg/kg body weight

Result: No effects on fertility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal injection

Developmental Toxicity: LOAEL: > 200 mg/kg body weight

prednisolone:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Subcutaneous Fertility: NOAEL: 1 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

Developmental Toxicity: LOAEL: 0,5 mg/kg body weight Result: Malformations were observed., Cleft palate

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 30 mg/kg body weight

Result: decreased blood formation

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: NOAEL: 25 mg/kg body weight

Result: No effects on foetal development

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

prednisolone:

Target Organs : Bone marrow, Adrenal gland, Liver

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cefapirin:

Species : Rat

LOAEL : >= 200 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

Application Route : Intraperitoneal

Target Organs : Blood Remarks : anemia

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 4 Months

Target Organs : Gastrointestinal tract

Species : Dog LOAEL : 100 mg/kg Application Route : Intramuscular Exposure time : 10 Months

Target Organs : Blood, Gastrointestinal tract

Remarks : anemia

prednisolone:

Species : Rat
LOAEL : 0,6 mg/kg
Application Route : Oral
Exposure time : 63 Days
Target Organs : Bone marrow

Species : Dog
LOAEL : 2,5 mg/kg
Application Route : Oral
Exposure time : 6 Weeks
Target Organs : Adrenal gland

Species : Rabbit
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 24 Weeks
Target Organs : Liver

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.1 28.09.2024 766831-00019 Date of first issue: 16.06.2016

Experience with human exposure

Components:

Cefapirin:

Ingestion : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea,

vaginitis, colitis, anorexia, Rash, anaphylaxis

prednisolone:

Ingestion : Symptoms: sodium retention, Headache, Vertigo, fluid reten-

tion, subcutaneous bleeding, striae, skin atrophy, menstrual

irregularities

SECTION 12: Ecological information

12.1 Toxicity

Components:

prednisolone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 85 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 160

mg/l

Exposure time: 72 h

EC50 (Pseudokirchneriella subcapitata (green algae)): > 160

mg/l

Exposure time: 72 h

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,23 mg/l Exposure time: 7 d

Species: Ceriodaphnia dubia (water flea)

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

Components:

prednisolone:

Partition coefficient: n-

log Pow: 1,46

octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.1 28.09.2024 766831-00019 Date of first issue: 16.06.2016

very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.1	28.09.2024	766831-00019	Date of first issue: 16.06.2016

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

Conditions of restriction for the following entries should be considered: Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) on substances that deplete the ozone

laver

Regulation (EU) 2019/1021 on persistent organic pollu:

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia:

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

Not applicable

Not applicable

Not applicable

lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H334 : May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Repr. : Reproductive toxicity
Resp. Sens. : Respiratory sensitisation

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Test-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 6.1 28.09.2024 766831-00019 Date of first issue: 16.06.2016

ing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance: PICCS - Philippines Inventory of Chemicals and Chemical Substances: (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Resp. Sens. 1 H334 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 6.1
 28.09.2024
 766831-00019
 Date of first issue: 16.06.2016